Gelatinase B/matrix metalloproteinase-9 cleaves interferon-β and is a target for immunotherapy

Brain

Volumn 126, Issue 6, 2003, Pages 1371-1381

  Nelissen, Inge ^a   Martens, Erik ^a   Van den Steen, Philippe E ^a   Proost, Paul ^a   Ronsse, Isabelle ^a   Opdenakker, Ghislain ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Gelatinase B; Inflammation; Interferon; Multiple sclerosis; Viral infection

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GELATINASE B; INTERFERON BETA SERINE; MINOCYCLINE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CHINESE HAMSTER; CONTROLLED STUDY; DRUG FORMULATION; DRUG TARGETING; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SYNTHESIS; FEMALE; IMMUNOPHARMACOLOGY; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MULTIPLE SCLEROSIS; NONHUMAN; OVARY CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; VIRUS INFECTION;

ANTIVIRAL AGENTS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE I, RECOMBINANT; INTERFERON-BETA; MATRIX METALLOPROTEINASE 9; MULTIPLE SCLEROSIS; PROTEIN CONFORMATION;

EID: 0038015502     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/awg129     Document Type: Article

References (47)

1. Armstrong JA. Cytopathic effect inhibition assay for interferon: microculture plate assay. Methods Enzymol 1981; 78: 381-7.
2. Baron S, Tyring SK, Fleischmann WR Jr, Coppenhaver DH, Niesel DW, Klimpel GR, et al. The interferons. Mechanisms of action and clinical applications. JAMA 1991; 266: 1375-83.
3. Bartholomé EJ, Van Aelst I, Koyen E, Kiss R, Willems F, Goldman M, et al. Human monocyte-derived dendritic cells produce bioactive gelatinase B: inhibition by IFN-beta. J Interferon Cytokine Res 2001; 21: 495-501.
4. Bauvois B, Dumont J, Mathiot C, Kolb J-P. Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons. Leukemia 2002; 16: 791-8.
5. Billiau A, Edy VG, Heremans H, Van Damme J, Desmyter J, Georgiades JA, et al. Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother 1977; 12: 11-5.
6. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration. Minocycline as a potential therapy for multiple sclerosis. Brain 2002; 125: 1297-308.
7. Clements JM, Cossins JA, Wells GM, Corkill DJ, Helfrich K, Wood LM, et al. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J Neuroimmunol 1997; 74: 85-94.
8. Cuzner ML, Opdenakker G. Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J Neuroimmunol 1999; 94: 1-14.
9. De Meester I, Korom S, Van Damme J, Scharpé S. CD26, let it cut or cut it down. Immunol Today 1999; 20: 367-75.
10. Derynck R, Remaut E, Saman E, Stanssens P, De Clercq E, Content J, et al. Expression of human fibroblast interferon gene in Escherichia coli. Nature 1980; 287: 193-7.
11. D'Haese A, Wuyts A, Dillen C, Dubois B, Billiau A, Heremans H, et al. In vivo neutrophil recruitment by granulocyte chemotactic protein-2 is assisted by gelatinase B/MMP-9 in the mouse. J Interferon Cytokine Res 2000; 20: 667-74.
12. Dubois B, D'Hooghe MB, De Lepeleire K, Ketelaer P, Opdenakker G, Carton H. Toxicity in a double-blind, placebo-controlled pilot trial with D-penicillamine and metacycline in secondary progressive multiple sclerosis. Mult Scler 1998; 4: 74-8.
13. Dubois B, Masure S, Hürtenbach U, Paemen L, Heremans H, van den Oord J, et al. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest 1999; 104: 1507-15.
14. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-60.
15. Galboiz Y, Shapiro S, Lahat N, Rawashdeh H, Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol 2001; 50: 443-51.
16. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992; 41: 29-34.
17. Gijbels K, Proost P, Masure S, Carton H, Billiau A, Opdenakker G. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res 1993; 36: 432-40.
18. Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 1994; 94: 2177-82.
19. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994; 91: 1198-205.
20. Hewson AK, Smith T, Leonard JP, Cuzner ML. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res 1995; 44: 345-9.
21. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. 1. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 1993; 43: 655-61.
22. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94.
23. Karpusas M, Nolte M, Benton CB, Meier W, Lipscomb WN, Goelz S. The crystal structure of human interferon beta at 2.2-A resolution. Proc Natl Acad Sci USA 1997; 94: 11813-8.
24. Karpusas M, Whitty A, Runkel L, Hochman P. The structure of human interferon-β: implications for activity. Cell Mol Life Sci 1998; 54: 1203-16.
25. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 1999; 122: 191-7.
26. Leppert D, Waubant E, Burk MR, Oksenberg JR, Hauser SL. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996; 40: 846-52.
27. Lukes A, Mun-Bryce S, Lukes M, Rosenberg GA. Extracellular matrix degradation by metalloproteinases and central nervous system diseases. Mol Neurobiol 1999; 19: 267-84.
28. Masure S, Billiau A, Van Damme J, Opdenakker G. Human hepatoma cells produce an 85 kDa gelatinase regulated by phorbol 12-myristate 13-acetate. Biochim Biophys Acta 1990; 1054: 317-25.
29. Mun-Bryce S, Rosenberg GA. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol 1998; 274: R1203-11.
30. Nelissen I, Ronsse I, Van Damme J, Opdenakker G. Regulation of gelatinase B in human monocytic and endothelial cells by PECAM-1 ligation and its modulation by interferon-beta. J Leukoc Biol 2002; 71: 89-98.
31. Opdenakker G, Van Damme J. Cytokine-regulated proteases in autoimmune diseases. Immunol Today 1994; 15: 103-7.
32. Opdenakker G, Rudd PM, Wormald M, Dwek RA, Van Damme J. Cells regulate the activities of cytokines by glycosylation. FASEB J 1995; 9: 453-7.
33. Opdenakker G, Van den Steen PE, Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 2001; 22: 571-9.
34. Özenci V, Kouwenhoven M, Teleshova N, Pashenkov M, Fredrikson S, Link H. Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. J Neuroimmunol 2000; 108: 236-43.
35. Paemen L, Olsson T, Söderström M, Van Damme J, Opdenakker G. Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur J Neurol 1994; 1: 55-63.
36. Paemen L, Martens E, Norga K, Masure S, Roets E, Hoogmartens J, et al. The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem Pharmacol 1996; 52: 105-11.
37. Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 2002; 51: 215-23.
38. Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 1993; 192: 1175-81.
39. Runkel L, Meier W, Pepinsky RB, Karpusas M, Whitty A, Kimball K, et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β). Pharm Res 1998; 15: 641-9.
40. Scagnolari C, Bellomi F, Turriziani O, Bagnato F, Tomassini V, Lavolpe V, et al. Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations. J Interferon Cytokine Res 2002; 22: 207-13.
41. Schönbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 1998; 161: 3340-6.
42. Stüve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Williams G, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996; 40: 853-63.
43. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000; 96: 2673-81.
44. Van den Steen PE, Proost P, Grillet B, Brand DD, Kang AH, Van Damme J, et al. Degradation of collagen type II by neutrophil gelatinase B: cleavage specificity, posttranslational modifications and remnant epitope generation in autoimmunity. FASEB J 2002; 16: 379-89.
45. Waubant E, Gee L, Miller K, Stabler G, Goodkin D. IFN-beta1a may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosis. J Interferon Cytokine Res 2001; 21: 181-5.
46. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nature Rev Neurosci 2001; 2: 502-11.
47. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 1999; 96: 13496-500.